CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
REVENUE:
Commercial revenue	$ 5,278,704	$ 1,951,892	$ 10,022,779	$ 3,782,039
Developmental revenue	5,973,711	6,494,937	10,830,176	8,911,440
Total revenue	11,252,415	8,446,829	20,852,955	12,693,479
OPERATING EXPENSES:
Cost of chemicals sold	142,540	218,417	245,202	317,037
Research and development	5,551,492	5,500,507	12,106,610	10,329,304
Selling, general and administrative	4,495,821	3,624,582	8,367,778	6,266,828
Patent costs	1,915,060	843,907	3,528,102	1,625,166
Royalty and license expense	218,255	168,560	420,039	288,620
Total operating expenses	12,323,168	10,355,973	24,667,731	18,826,955
Operating loss	(1,070,753)	(1,909,144)	(3,814,776)	(6,133,476)
INTEREST INCOME	184,877	61,125	280,350	136,780
INTEREST EXPENSE	(8,430)	(5,648)	(18,068)	(12,707)
GAIN (LOSS) ON STOCK WARRANT LIABILITY	4,496,367	(2,582,428)	(4,429,845)	(1,869,185)
INCOME (LOSS) BEFORE INCOME TAX (EXPENSE) BENEFIT	3,602,061	(4,436,095)	(7,982,339)	(7,878,588)
INCOME TAX (EXPENSE) BENEFIT	(289,361)		(585,817)	464,162
NET INCOME (LOSS)	$ 3,312,700	$ (4,436,095)	$ (8,568,156)	$ (7,414,426)
NET INCOME (LOSS) PER COMMON SHARE:
Basic	$ 0.07	$ (0.12)	$ (0.20)	$ (0.20)
Diluted	$ (0.03)	$ (0.12)	$ (0.20)	$ (0.20)
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME (LOSS) PER COMMON SHARE:
Basic	45,024,373	37,362,176	41,977,113	37,196,741
Diluted	45,201,175	37,362,176	41,977,113	37,196,741